ACELYRIN Is Maintained at Overweight by Wells Fargo
Wells Fargo Maintains Overweight on Acelyrin, Lowers Price Target to $13
Macy's, Dave & Buster's, Bausch + Lomb And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
Piper Sandler Maintains Acelyrin(SLRN.US) With Buy Rating, Maintains Target Price $20
A Quick Look at Today's Ratings for Acelyrin(SLRN.US), With a Forecast Between $6 to $20
Acelyrin Shares Are Trading Lower After the Company Announced Its Phase 2b/3 Study of Izokibep Did Not Meet Its Primary Endpoint, With Secondary Endpoints Also Failing to Achieve Statistical Significance.
AW138 : thank you sir, always appreciate your posts
DaTrader AW138 : I second that
WILLEE9ice : tons of thanks master, you have has done the jobs
Jenna Ragan : Thank you kindly
Tottigol10 : I can't understand unfortunately..any recommendations on where i can start to study and get more into it?
View more comments...